theranostics

Blue Earth Diagnostics Produces New Data Supporting FDA Approval of Prostate Cancer Imaging Agent

Fusion Pharmaceuticals to Acquire Prostate Cancer Radiopharmaceutical Program From RadioMedix

Actinium Pharmaceuticals, NCI Ink Research Agreement on Targeted Radiopharmaceutical

Isoray, Viewpoint Molecular Targeting Complete Merger to Advance Targeted Radiopharmaceuticals

Ratio Therapeutics Raises $20M in Series A Financing

Viewpoint Molecular Targeting Treats First Neuroendocrine Cancer Patients With Radiopharmaceutical

Novartis' Pluvicto Approved in Europe for PSMA-Positive Castration-Resistant Prostate Cancer

Novartis to Seek Pluvicto Approval in Another Advanced PSMA-Positive Prostate Cancer Setting

Sofie Biosciences to Begin Trial of Fluorine-Labeled PET Diagnostic Imaging Agent for GI Cancers

ICPO Foundation, PreMIT Collaborate to Establish Theranostic Centers

Clarity Pharmaceuticals to Evaluate GRPr-Targeting Radiopharmaceutical in mCRPC Trial

Lantheus Licenses Two Late-Stage Radiopharmaceutical Candidates From Point Biopharma

ImaginAb, Parthenon Ink Licensing Deal to Use PET Imaging in Immunotherapy Trial

In Brief This Week: Caris Life Sciences, Radiopharm Theranostics, Tempus

ImaginAb Doses First Patient in Study of CD8-Targeted PET Imaging Agent in Australia

Nihon Medi-Physics to Begin Phase I Trial of Theranostic Antibody NMK89

Blue Earth Diagnostics, Siemens Healthineers Partner on Prostate Cancer Theranostics, PET Imaging

EMA's CHMP Recommends Novartis' Pluvicto for PSMA-Positive mCRPC